Key Points
- Ra Capital Management, L.P. (a director) bought 213,099 shares of Climb Bio on Dec. 11 at an average price of $2.18 (≈$464,556), increasing its direct holdings to 3,294,856 shares — a 6.91% ownership rise — as disclosed in an SEC Form 4.
- Ra Capital also purchased an additional 101,462 shares on Dec. 12 at $2.86 (≈$290,181), and the stock subsequently traded up ~27% to open at $3.81, with a 12‑month range of $1.05–$4.82 and a market cap of about $259.8 million.
- Analyst sentiment is mixed: the consensus rating is a "Moderate Buy" with an average target of $9.00 despite some downgrades, and Climb Bio remains a clinical‑stage biotech developing an anti‑CD19 monoclonal antibody.
Climb Bio, Inc. (NASDAQ:CLYM - Get Free Report) Director Ra Capital Management, L.P. bought 101,462 shares of Climb Bio stock in a transaction dated Friday, December 12th. The shares were acquired at an average price of $2.86 per share, with a total value of $290,181.32. Following the completion of the purchase, the director owned 3,396,318 shares in the company, valued at approximately $9,713,469.48. The trade was a 3.08% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Ra Capital Management, L.P. also recently made the following trade(s):
- On Thursday, December 11th, Ra Capital Management, L.P. purchased 213,099 shares of Climb Bio stock. The stock was bought at an average price of $2.18 per share, with a total value of $464,555.82.
Climb Bio Price Performance
CLYM opened at $3.81 on Tuesday. Climb Bio, Inc. has a 12-month low of $1.05 and a 12-month high of $4.82. The stock has a market capitalization of $259.78 million, a PE ratio of -5.01 and a beta of -0.06. The firm's fifty day moving average price is $1.97 and its 200 day moving average price is $1.80.
Climb Bio (NASDAQ:CLYM - Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.03). On average, equities research analysts forecast that Climb Bio, Inc. will post -1.57 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in CLYM. Peapod Lane Capital LLC grew its holdings in shares of Climb Bio by 1.1% during the 3rd quarter. Peapod Lane Capital LLC now owns 561,866 shares of the company's stock valued at $1,129,000 after purchasing an additional 6,199 shares during the last quarter. ADAR1 Capital Management LLC raised its stake in Climb Bio by 11.9% during the third quarter. ADAR1 Capital Management LLC now owns 133,530 shares of the company's stock worth $268,000 after buying an additional 14,210 shares during the last quarter. Vanguard Personalized Indexing Management LLC bought a new position in Climb Bio during the third quarter worth $29,000. AQR Capital Management LLC acquired a new position in Climb Bio in the first quarter valued at $27,000. Finally, UBS Group AG boosted its position in Climb Bio by 6.0% during the third quarter. UBS Group AG now owns 405,404 shares of the company's stock valued at $815,000 after acquiring an additional 22,922 shares during the last quarter. Institutional investors and hedge funds own 69.76% of the company's stock.
Analysts Set New Price Targets
A number of analysts recently weighed in on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Climb Bio in a report on Wednesday, October 8th. William Blair initiated coverage on shares of Climb Bio in a research report on Thursday, October 16th. They issued an "outperform" rating for the company. BTIG Research reissued a "buy" rating and issued a $8.00 price target on shares of Climb Bio in a research report on Thursday, October 16th. HC Wainwright assumed coverage on Climb Bio in a research report on Monday, October 13th. They set a "buy" rating and a $9.00 price objective on the stock. Finally, Wall Street Zen cut shares of Climb Bio from a "hold" rating to a "strong sell" rating in a research note on Saturday, November 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Climb Bio has an average rating of "Moderate Buy" and a consensus price target of $9.00.
Read Our Latest Stock Analysis on Climb Bio
About Climb Bio
(
Get Free Report)
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
